1. Articles in category: News

    1-24 of 201 1 2 3 4 5 6 7 8 9 »
    1. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.

      Pediatr Hematol Oncol. 2017 Nov 17;:1-12

      Authors: Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J

      Read Full Article
      Mentions: Treatment MYCN
    2. PRecISion Medicine for Children With Cancer

      PRecISion Medicine for Children With Cancer

      Conditions :   Childhood Cancer;   Childhood Solid Tumor;   Childhood Brain Tumor;   Childhood Leukemia;   Refractory Cancer;   Relapsed Cancer Intervention :   Diagnostic Test: Molecular profiling and drug testing Sponsors :   Sydney Children's Hospitals Network;   Children's Cancer Institute Australia;   Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG);   Garvan Institute of Medical Research;   German Cancer Research Center (DKFZ) Recruiting

      Read Full Article
    3. Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.

      Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System.

      Anticancer Res. 2017 11;37(11):5911-5918

      Authors: Berger M, VON Schweinitz D

      Abstract Neuroblastoma is the most common solid extracranial malignant tumor in children. Despite recent advances in the treatment of this heterogenous tumor with surgery and chemotherapy, the prognosis in advanced stages remains poor.

      Read Full Article
    4. Emerging and investigational therapies for neuroblastoma.

      Emerging and investigational therapies for neuroblastoma.

      Expert Opin Orphan Drugs. 2017;5(4):355-368

      Authors: Applebaum MA, Desai AV, Glade Bender JL, Cohn SL

      Abstract INTRODUCTION: Treatment for children with clinically aggressive, high-risk neuroblastoma remains challenging. Less than 50% of patients with high-risk neuroblastoma will survive long-term with current therapies, and survivors are at risk for serious treatment-related late toxicities.

      Read Full Article
      Mentions: Treatment
    5. New study finds childhood cancer survivors commonly stay at jobs to keep health insurance

      New study finds childhood cancer survivors commonly stay at jobs to keep health insurance

      ( University of Utah Health ) The results of a national cancer survey find a significant number of childhood cancer survivors are worried about keeping their health insurance, to the point of letting it affect their career decisions. The findings were published today in JAMA Oncology.

      Read Full Article
    6. Zebrafish as a model to study neuroblastoma development.

      Zebrafish as a model to study neuroblastoma development.

      Cell Tissue Res. 2017 Oct 13;:

      Authors: Casey MJ, Stewart RA

      Abstract Neuroblastoma is a pediatric solid tumor arising from embryonic neural crest progenitor cells that normally generate the peripheral sympathetic nervous system.

      Read Full Article
      Mentions: ALK
    7. Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors.

      Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors.

      Pediatr Surg Int. 2017 Oct 10;:

      Authors: Hishiki T, Mise N, Harada K, Ihara F, Takami M, Saito T, Terui K, Nakata M, Komatsu S, Yoshida H, Motohashi S

      Read Full Article
    8. Diet, exercise modifications can have ‘tremendous impact’ on pediatric cancer outcomes

      Joya Chandra Keri Schadler Diet and exercise may improve treatment outcomes among pediatric patients with cancer, according to a study conducted at The University of Texas MD Anderson Children’s Cancer Hospital. In addition, introducing energy balance interventions may reduce the risk for late effects during survivorship. Researchers at MD Anderson reviewed 67 pediatric oncology studies to evaluate the relationship between diet and exercise.

      Read Full Article
      Mentions: Treatment
    9. Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.

      Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients.

      Carcinogenesis. 2017 Aug 29;:

      Authors: Russo R, Cimmino F, Pezone L, Manna F, Avitabile M, Langella C, Koster J, Casale F, Raia M, Viola G, Fischer M, Iolascon A, Capasso M

      Read Full Article
    10. Study Identifies Patients Who Benefit Most From Dinutuximab-based Immunotherapy

      Using data from a randomized phase III clinical trial of neuroblastoma patients (treated with or without immunotherapy) performed by the Children’s Oncology Group, researchers from the University of Wisconsin School of Medicine and Public Health found that a subset of patients, identified by the presence of a certain set of genes, were more likely to benefit from […]

      The post Study Identifies Patients Who Benefit Most From Dinutuximab-based Immunotherapy appeared first on Healthcanal.com.

      Read Full Article
      Mentions: Immunotherapy
    11. A Cell-Cycle "Safe Space" for Surviving Chemotherapy.

      A Cell-Cycle "Safe Space" for Surviving Chemotherapy.

      Cell Syst. 2017 Sep 27;5(3):161-162

      Authors: Arora M, Spencer SL

      Abstract Live-cell imaging demonstrates that a subset of neuroblastoma cells evades chemotherapy-induced death if they are in early G1 phase of the cell cycle at the time of drug treatment and have sufficiently high levels of MYCN.

      PMID: 28957649 [PubMed - in process]

      Read Full Article
    12. GD2 Specific CAR and Interleukin-15 Expressing Autologous NK T-cells to Treat Children With Neuroblastoma

      GD2 Specific CAR and Interleukin-15 Expressing Autologous NK T-cells to Treat Children With Neuroblastoma

      Condition :   Neuroblastoma Interventions :   Genetic: GINAKIT Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine Sponsors :   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital Not yet recruiting

      Read Full Article
      Mentions: T-Cells
    13. Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.

      Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.

      J Pediatr Surg. 2017 Aug 26;:

      Authors: Kawakubo N, Tanaka S, Kinoshita Y, Tajiri T, Yonemitsu Y, Taguchi T

      Abstract PURPOSE: In preclinical trails, we reported the antitumor effect of dendritic cells activated with Sendai virus (rSeV/DC) combined with γ-irradiation against neuroblastoma.

      Read Full Article
    14. GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma.

      Cancer Discov. 2017 Sep 22;:

      Authors:

      Abstract A GPC2-targeting antibody-drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX.

      PMID: 28939655 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Antibody
    15. When good immune cells turn bad

      When good immune cells turn bad

      Investigators at the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles have identified new findings about an immune cell - called a tumor-associated macrophage - that promotes cancer instead of fighting it. They have identified the molecular pathway, known as STAT3, as the mechanism the immune cell uses to foster neuroblastoma, a pediatric cancer, and have demonstrated use of a clinically available agent, ruxolitinib, to block the pathway.

      Read Full Article
    16. Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.

      Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.

      Bioorg Med Chem Lett. 2017 Sep 09;:

      Authors: Takahashi N, Koyama S, Hasegawa S, Yamasaki M, Imai M

      Abstract Neuroblastoma is an aggressive and drug-resistant refractory cancer.

      Read Full Article
      Mentions: Refractory
    17. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.

      Expert Opin Investig Drugs. 2017 Sep 14;:

      Authors: Amoroso L, Haupt R, Garaventa A, Ponzoni M

      Abstract INTRODUCTION: Neuroblastoma (NB) is an embryonal tumor originating from undifferentiated neural crest cell, highly heterogeneous ranging from spontaneous regression to progression despite multimodal treatments.

      Read Full Article
      Mentions: Treatment
    18. Tandem thiotepa with autologous hematopoietic cell rescue in patients with recurrent, refractory, or poor prognosis solid tumor malignancies

      Background: The purpose of this study was to determine the feasibility and tolerability of tandem courses of high-dose thiotepa with autologous hematopoietic cell rescue (AHCR) in patients with recurrent, refractory solid tumors who were ineligible for a single course of high-dose therapy due to greater than minimal residual disease. Patients with decreased hearing or poor renal function were eligible.

      Read Full Article
      Mentions: Refractory
    19. Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma.

      Cancer Cell. 2017 Sep 11;32(3):271-273

      Authors: Malone CF, Stegmaier K

      Abstract In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in neuroblastoma. They show that GPC2 is selectively expressed on the cell surface of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.

      Read Full Article
      Mentions: Antibody
    20. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers

      Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy--harnessing the immune system in medical treatments.

      In cell cultures and animal models, a potent drug attached to an...

      Read Full Article
      Mentions: Immunotherapy
    21. Modulating T-cell metabolism uncovers new technology for enhancing immunotherapy

      Modulating T-cell metabolism uncovers new technology for enhancing immunotherapy

      T lymphocytes found in tumors and implicated in killing tumor cells cope with the shortage of oxygen and nutrients in the tumor microenvironment by using fat as the main source of energy. Promoting a switch from glucose to fatty acid to generate energy enhances T cell antitumor activity. These findings from a study conducted at The Wistar Institute were published in the journal Cancer Cell.

      Read Full Article
    22. Cell surface protein may offer big target in treating high-risk childhood cancers

      Cell surface protein may offer big target in treating high-risk childhood cancers

      ( Children's Hospital of Philadelphia ) Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy -- harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.

      Read Full Article
    1-24 of 201 1 2 3 4 5 6 7 8 9 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) Imaging
    2. (1 articles) MYCN
  4. General Informations in the News

    1. (1 articles) Treatment